Drug Trial Radar · NCT05440851
Platform of Randomized Adaptive Clinical Trials in Critical Illness
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
6,250
Planned (sponsor's estimate)
Start
Apr 30, 2023
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- University Health Network, TorontoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 1, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
PRACTICAL is a randomized multifactorial adaptive platform trial for acute hypoxemic respiratory failure (AHRF). This platform trial will evaluate novel interventions for patients with AHRF across a range of severity states (i.e., not intubated, intubated with lower or higher respiratory system elastance, requiring extracorporeal life support) and across a range of investigational phases (i.e., preliminary mechanistic trials, full-scale clinical trials). AHRF is a common and life-threatening clinical syndrome affecting millions globally every year. Patients with AHRF are at high risk of death and long-term morbidity. Patients who require invasive mechanical ventilation are at risk of ventilator-induced lung injury and ventilator-induced diaphragm dysfunction. New treatments and treatment strategies are needed to improve outcomes for these very ill patients. Utilizing advances in Bayesian adaptive trial design, the platform will facilitate efficient yet rigorous testing of new treatments for AHRF, with a particular focus on mechanical ventilation strategies and extracorporeal life support techniques as well as pharmacological agents and new medical devices. The platform is designed to enable evaluation of novel interventions at a variety of stages of investigation, including pilot and feasibility trials, trials focused on mechanistic surrogate endpoints for preliminary clinical evaluation, and full-scale clinical trials assessing the impact of interventions on patient-centered outcomes. A domain is defined as a set of interventions that are intended to act on specific mechanisms of injury using different variations of a common therapeutic strategy. A domain may also be a non-interventional study that addresses observational research questions by collecting specific data or outcomes that are not collected as part of other domains. Domains are intended to function independently of each other, allowing independent evaluation of multiple therapies and mechanistic pathways within the same patient. Once feasibility is established, Bayesian adaptive statistical modelling will be used to evaluate treatment efficacy at regular interim adaptive analyses of the pre-specified outcomes for each intervention in each domain. These adaptive analyses will compute the posterior probabilities of superiority, futility, inferiority, or equivalence for pre-specified comparisons within domains. Each of these potential conclusions will be pre-defined prior to commencing the intervention trial. Decisions about trial results (e.g., concluding superiority or equivalence) will be based on pre-specified threshold values for posterior probability. The primary outcome of interest, the definitions for superiority, futility, etc. (i.e., the magnitude of treatment effect) and the threshold values of posterior probability required to reach conclusions for superiority, futility etc., will vary from intervention to intervention depending on the phase of investigation and the nature of the intervention being evaluated. All of these parameters will be pre-specified as part of the statistical design for each intervention trial. In general, domains will be designed to evaluate treatment effect within four discrete clinical states: non-intubated patients, intubated patients with low respiratory system elastance (\<2.5 cm H2O/(mL/kg)), intubated patients with high respiratory system elastance (≥2.5 cm H2O/(mL/kg)), and patients requiring extracorporeal life support. Where appropriate, the model will specify dynamic borrowing between states to maximize statistical information available for trial conclusions. In this perpetual trial design, different interventions may be added or dropped over time. Where possible, the platform will be embedded within existing data collection repositories to enable greater efficiency in outcome ascertainment. Standardized systems for acquiring both physiological and biological measurements are embedded in the platform, to be acquired at sites with appropriate training, expertise, and facilities to collect those measurements.
Conditions
- Respiratory Insufficiency
- Extracorporeal Membrane Oxygenation Complication
- Mechanical Ventilation Pressure High
Interventions
Ultra-Protective Ventilation Facilitated by Extracorporeal SupportOther
Patients randomized to this intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.
Lung-Protective Ventilation (LPV)Other
Patients randomized to LPV will receive standard of care lung-protective ventilation with conventional limits on tidal volume and plateau airway pressure.
Driving Pressure-Limited Ventilation (DPL)Other
Patients randomized to DPL will receive mechanical ventilation set to maintain a safe limit on driving pressure and plateau airway pressure, without less for the tidal volume.
Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS)Other
Patients randomized to LDPVS will have ventilation and sedation adjusted to maintain lung-distending pressure and respiratory effort in a safe target range.
Early Cohort corticosteroid doseDrug
Patients randomized to receive corticosteroids will receive dexamethasone 20mg daily for 5 days and then 10mg for an additional 5 days, for a total of 10 days from the time of randomization (or until ICU discharge or death, whichever comes first); after 10 days dexamethasone will be stopped without a taper.
Extended Cohort corticosteroid doseDrug
Patients randomized to receive extended corticosteroids will receive dexamethasone 10mg for an additional 10 days. At the end of the additional 10 days (day 20 of corticosteroids), the dexamethasone dose will be halved to 5mg for another 5 days (to reduce the risk of adrenal insufficiency) and then stopped (a total of 25 days or until ICU discharge or death, whichever comes first).
Usual care without routine corticosteroidsDrug
Patients randomized to this arm will be managed according to usual care. They will receive corticosteroids only if prescribed by the clinician.
Usual care without extending corticosteroidsDrug
Corticosteroids will stop after 10 days. Other management will be according to usual care. Patients will receive corticosteroids only if prescribed by the clinician.
Usual care with fludrocortisoneDrug
Best practice standard of care prescribed by treating team + fludrocortisone 50μg enterally daily for 7 days.
Usual care without fludrocortisoneDrug
Best practice standard of care prescribed by treating team without fludrocortisone. After randomization, if a clinical indication develops for fludrocortisone as part of standard of care, administration of fludrocortisone is not prohibited. Any fludrocortisone administered to participants in the control arm will be documented.
Drug 4 mL:Drug
4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.
Drug 40 mg:Drug
40 mg of nebulized furosemide in 4 mL of saline nebulized over 30 minutes every 6 hours
PEEP-20Other
fixed high positive end-expiratory pressure at 20 cmH2O
PEEP-AOPOther
positive end-expiratory pressure set according to airway opening pressure
PEEP-10Other
fixed lower positive end-expiratory pressure at 10 cmH2O
VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitationOther
Patients randomized to this intervention group will receive VV-ECMO where the sedation will be reduced and the ventilator will will be adjusted to facilitate spontaneous breathing.
Electrical impedance tomography (EIT)Other
Patients randomized to EIT will have PEEP titration compared via the Overdistension Collapse Intercept (ODCL) versus that obtained using a standard high PEEP table.
no treatment / intervention arm is involvedOther
This trial is a prospective, multicenter, observational study (no treatment arm is involved).
Usual careOther
Patients will be treated according to usual care.
Early Routine IMTOther
* Training commences once patients meet readiness to wean criteria * 3 sets of 10 breaths, delivered twice daily using a device placed at the airway opening to apply an external resistive pressure load, until hospital discharge, death, or day 45 after randomization, whichever occurs first. * Device load will initially be set to 30% of the MIP. * Device load will be titrated upward (in increments of 5-10% of MIP, to a maximum of 60% of MIP) as needed to achieve a modified Borg dyspnea score of 7/10 or visible accessory muscle use.
no treatment / intervention arm is involved.Other
This trial is a prospective, multicenter, observational study (no treatment arm is involved).
Primary outcomes
What the sponsor says the trial is designed to measure.
- EXPAND-ECLS domain - determine the feasibility of recruiting 100 patients over 2 years of active enrolment, as well as assess the rate of participant recruitment and understand the barriers to enrollment.Time frame: 2 years of active site enrollment.
- FLUDRO-1 and IMV domains - ventilator-free days to day 28 in DPL vs LPV (DRIVE RCT)Time frame: Day 28 post randomization
- IMV domain - adherence to LDPVS management (LANDMARK RCT)Time frame: Day 28
- IMV domain - probability of achieving and maintaining lung- and diaphragm-protective targets during mechanical ventilation (LANDMARK RCT)Time frame: Day 28
- IMV domain - protocol adherence (EIT intervention)Time frame: Day 9
- CORT-E2 domain - 60-day mortality from the day of randomizationTime frame: Day 60
- FLUDRO-1 domain - Successful enrollment of participantsTime frame: 18-month enrolment period across three platform trials (PRACTICAL, REMAP-CAP and ATTACC-CAP)
- FAST-3 domain - Advanced respiratory support free daysTime frame: Day 28
- IMV-ECLS domain - feasibility of enrollment and protocol adherenceTime frame: For feasibility of enrollment: 2 years of active site enrollment; For protocol adherence, these will be evaluated at 7 days (once the intervention period ends)
- ESCAPE domain - 28-day all-cause mortalityTime frame: 28-day
- IMPROV domain - recruitment rate, protocol adherence, and vital statusTime frame: Throughout trial enrollment for recruitment rate and protocol adherence, and up to day 90 for vital status.
- WAVEFORM domainTime frame: considering death as a competing event
Locations
103 sites in 10 countries. Site status is shown where the registry gives one.
University of Arizona
Tucson, Arizona · Recruiting
University of California Los Angeles (UCLA)
Los Angeles, California · Recruiting
University of San Diego (UCSD)
San Diego, California · Recruiting
University of California San Francisco
San Francisco, California · Recruiting
University of Colorado Hospital
Aurora, Colorado · Recruiting
University of Kentucky
Lexington, Kentucky · Recruiting
University of Maryland Medical System
Baltimore, Maryland · Recruiting
The Johns Hopkins Medicine
Baltimore, Maryland · Recruiting
VA Ann Arbor Healthcare System
Ann Arbor, Michigan · Recruiting
University of Michigan Health
Ann Arbor, Michigan · Recruiting
Washington University
St Louis, Missouri · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
Mount Sinai New York City
New York, New York · Recruiting
Columbia University Irving Medical Center
New York, New York · Recruiting
Wake Forest University School of Medicine
Winston-Salem, North Carolina · Recruiting
University of Cincinnati College of Medicine
Cincinnati, Ohio · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Oregon Health & Science University (OHSU)
Portland, Oregon · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, Pennsylvania · Recruiting
Rhode Island Hospital
Providence, Rhode Island · Recruiting
Medical University of South Carolina (MUSC)
Charleston, South Carolina · Recruiting
Vanderbilt university medical center
Nashville, Tennessee · Recruiting
Texas Tech
El Paso, Texas · Recruiting
University of Utah Health
Farmington, Utah · Recruiting
Sentara Health
Norfolk, Virginia · Recruiting
Westmead Hospital
Westmead, Australia · Recruiting
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia · Recruiting
Nepean Hospital
Kingswood, New South Wales, Australia · Recruiting
Wollongong Hospital
Wollongong, New South Wales, Australia · Recruiting
The Prince Charles Hospital
Chermside, Queensland, Australia · Recruiting
Flinders Medical Centre
Bedford Park, Southern Adelaide, Australia · Recruiting
St Vincent Hospital, Sydney
Darlinghurst, Sydney, Australia · Recruiting
Bendigo Health Victoria
Bendigo, Victoria, Australia · Recruiting
Peninsula University Hospital
Frankston, Victoria, Australia · Recruiting
University Hospital Geelong
Geelong, Victoria, Australia · Recruiting
The Austin Hospital
Heidelberg, Victoria, Australia · Recruiting
University of Calgary
Calgary, Alberta, Canada · Recruiting
University of Alberta/Edmonton University Hospital
Edmonton, Alberta, Canada · Recruiting
Showing 40 of 103 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.